Ectica Technologies is an innovative Swiss life science company dedicated to advance pre-clinical drug discovery by offering new tools, materials and technologies to the biotech and pharma industry.
Ectica Technologies is a manufacturer of high-tech hydrogel-based tools and hydrogel specialty chemicals. In few years only, our company managed to become the trusted manufacturer for fully synthetic hydrogel products of leading life science and biopharma companies in North America, Europe and Asia. Products are manufactured under Ectica’s brand or under Private Labels.

The flagship product is called the 3DProSeed hydrogel well plate. It is a 96-well black glass bottom imaging plate featuring pre-casted, optically transparent fully synthetic hydrogels in each well. The hydrogels are manufactured with state-of-the art Poly(ethylene glycol) (PEG) -bioconjugates. The hydrogels are delivered hydrated ready for cell seeding. The goal of this product is to combine the advantages of hydrogel-based cultures with the same workflow of standard polystyrene cultureware. The key innovation is the patented hydrogel surface which consists of an in-depth crosslinking density gradient promoting the active infiltration of cells into the hydrogel and establishment of a 3D environment. The seeding process can be repeated multiple times with different cell populations during the assay (sequential seeding). The sequential seeding enables the establishment of a stromal environment (e.g. fibroblastic matrix, endothelial cells, adipocytes, hepatic stellate cells etc…) followed by the addition of tumor cells to the preformed stromal model, to address complex questions in cancer biology. A product presentation can be downloaded in the Marketing section.

Ectica Technologies has a skilled team of scientists to engage in collaborative projects with biotech and pharma clients interested in a rapid and smooth integration of our technologies into the existing project and workflows. Our skills are primarily focused on oncology research and discovery, specifically on the investigation of tumor-stroma interactions, ex-vivo and in screening-compatible settings.